News Mar 28, 2019

Traphaco's Annual General Meeting of Shareholders in 2019

In the morning of March 28th, 2019, Traphaco Joint Stock Company held the Annual General Meeting of Shareholders in 2019. The Meeting passed through the report on the production and business activities in 2018 and the orientation of the year 2019, financial report of 2018, report on profit distribution plan, dividend payment for 2018 ... and many other important reports.

2018 was a pressure year and did not fulfill the objectivegoals for Traphaco. The revenue and profit index are low compared to the setting plan and decreased over the same previous period. However, Traphaco's strategy that implemented in 2018 has achieved certain goals of branding, customers, new products, quality management, and employees aspects ... creating important premises for the development in the long term.

The company also boldly invested in research and development when signing bio-equivalence research contracts, signing cooperation with Hanoi University of Pharmacy and launching the technology transfer project with Daewoong Koreapartneron March, 2019.

In 2018, although the Board of Directors had some certain changes in personnel, they still fulfilled the roles according to provisions of law&charter of Traphaco Joint Stock Company andproactively supported the Executive Board to implement the objectives of Company.

In 2018, the consolidated revenue of Traphaco was 1,788 billion VND, reaching 75% of the 2018 plan (decreased 4% compared to 2017). Regarding profit targets: Profit after tax of the parent company reached VND 156.27 billion (decreased 35% compared to 2017). In 2018, the average income of employees reached 20.38 million / month, decreased 6.8% compared to 2017, but still reached a good level compared to theaverage market. Traphaco has made a 20% advancedividend to shareholders in January 2019.

At the congress, Mr. Nguyen Anh Tuan - Vice Chairman of the Board of Directors commented on 4 big contents: 1/ The context of the whole market is challenging in 2018 and Traphaco's moves in maintaining the position 1 on the OTC market and investment in the ETC market; 2/ Advantages of Traphaco when it is proactive with the source of pharmaceutical materials, reducing adverse impacts when the the price of raw materials and materials increases; 3/ Board of Directors strengthens the cost control activities in 2019 on reasonable criteria so as not to affect growth, without losing market shares and also to take market shares from competitors; 4 / Strengthen brand identity and promote marketing activities that need to be focused, in order to catch up with the new trend (chain of pharmacies, ...).

Mr. Lee ChoongHwan - representative of MAGBI Fund has shared about the future direction of Traphaco and expected shareholders' contribution to the development of the company.

There have been many questions raised by shareholders regarding the development plan of OTC and ETC systems, key products and functional food segments, capital raising schedule, etc. The BOD has satisfactorily answered all of the shareholders'opinions, questions and receive many shareholders' contributions.

The Annual General Meeting has voted and unanimously approved the reports, directions, strategies for sustainable development and other important indicators. The Meeting also voted unanimously and approved the fullly Resolution of the Annual General Meeting of Shareholders 2018 with the approval rate of 99.32% of the total votes of attending shareholders.

Some photos at the meeting:

Mrs. Vu Thi Thuan - Chairman of Board of Directors reports on the production activities result for the year 2018

Mr. Nguyen Anh Tuan - Vice Chairman of Board of Directors presents the financial report for the year 2019

Mr. Tran Tuc Ma - General Director answers all the questions of share holders

The congress voted unanimously and approved the fully resolution of the Annual General Meeting for the year 2018.